Management strategy in aplastic anemia patients with HBV infection following intensive immunosuppressive therapy in Chinese cohort: prophylactic antiviral therapy may not be necessary with close monitoring

Key Points

• To evaluate the necessity of prophylactic antiviral therapy in aplastic anemia patients with chronic HBV infection receiving immunosuppressive therapy.
• Evaluated outcomes of aplastic anemia patients with chronic and resolved HBV infections.
• Monitored patients undergoing intensive immunosuppressive therapy.
• Implemented stringent surveillance methods for patients with resolved HBV infections.
• Prophylactic antiviral therapy is necessary for patients with chronic HBV infection during immunosuppressive therapy.
• For patients with resolved HBV infection, close monitoring is sufficient without prophylactic antiviral drugs.